Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2024
Communicable Diseases Intelligence · 2025
DOI: 10.33321/cdi.2025.49.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Christiane Stehmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Florey Institute, The University of Melbourne, Victoria, 3010, Australia. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome, Population Surveillance. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nationwide surveillance of Creutzfeldt-Jakob disease (CJD) and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable improvements have been developed in pre-mortem diagnostics; in the delineation of new disease subtypes; and in heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2024. Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2024, a total of 760 domestic CSF specimens were referred for diagnostic testing and 88 persons with suspected human prion disease were formally added to the national register. As of 31 December 2024, approximately half (42) of the 83 initial case notifications for 2024 remain classified as ‘incomplete’; 21 cases were classified as ‘definite’ and 17 as ‘probable’ prion disease; three cases were excluded through neuropathological examination. For 2024, seventy-two percent of all suspected human-prion-disease-related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified in Australia during 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
- Department of Medicine, The University of Melbourne, Victoria, 3010, Australia.
- The Florey Institute, The University of Melbourne, Victoria, 3010, Australia; The Alfred Hospital, Department of Anatomical Pathology, 55 Commercial Rd, Melbourne Vic 3004 Australia.
- The Florey Institute, The University of Melbourne, Victoria, 3010, Australia; Department of Medicine, The University of Melbourne, Victoria, 3010, Australia. s.collins@unimelb.edu.au.
Zitieren
APA
Stehmann, C., Senesi, M., Sarros, S., McGlade, A., Lewis, V., Agustina, P., Barber, D., Klug, G., Holper, S., McLean, C., Masters, C., & Collins, S. (2025). Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2024. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.050
Vancouver
Stehmann C, Senesi M, Sarros S, McGlade A, Lewis V, Agustina P, et al. Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2024. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.050
BibTeX
@article{Stehmann2025,
author = {Stehmann, Christiane and Senesi, Matteo and Sarros, Shannon and McGlade, Amelia and Lewis, Victoria and Agustina, Priscilla and Barber, Daniel and Klug, Genevieve and Holper, Sarah and McLean, Catriona and Masters, Colin and Collins, Steven},
title = {Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2024},
journal = {Communicable Diseases Intelligence},
year = {2025},
doi = {10.33321/cdi.2025.49.050}
}
EUVIMED